Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence
Abstract Focal Adhesion Kinase (FAK) is a 125-kDa cytoplasmic protein kinase that is
implicated in several cellular functions. This protein is an attractive molecular target for …
implicated in several cellular functions. This protein is an attractive molecular target for …
The role of interleukin‐1 in inflammatory and malignant human skin diseases and the rationale for targeting interleukin‐1 alpha
MJ Bou‐Dargham, ZI Khamis… - Medicinal research …, 2017 - Wiley Online Library
Inflammation plays a major role in the induction and progression of several skin diseases.
Overexpression of the major epidermal proinflammatory cytokines interleukin (IL) 1 alpha (IL …
Overexpression of the major epidermal proinflammatory cytokines interleukin (IL) 1 alpha (IL …
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling
R Tripathi, Z Liu, A Jain, A Lyon, C Meeks… - Nature …, 2020 - nature.com
Metastatic melanoma remains an incurable disease for many patients due to the limited
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic …
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic …
Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung …
WJ Hua, H Yeh, ZH Lin, AJ Tseng, LC Huang, WL Qiu… - Cancer Letters, 2023 - Elsevier
Epidermal growth factor receptor (EGFR) abnormalities relevant to tumor progression. A
newly developed strategy for cancer therapy is induction of EGFR degradation. GMI, an …
newly developed strategy for cancer therapy is induction of EGFR degradation. GMI, an …
Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
ES Knudsen, V Kumarasamy, A Ruiz, J Sivinski… - Oncogene, 2019 - nature.com
Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially
loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated …
loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated …
Evidence-based medicine and precision medicine: complementary approaches to clinical decision-making
Evidence-based medicine is widely promoted for decision-making in health care and is
associated with improved patient outcomes. Critics have suggested that evidence-based …
associated with improved patient outcomes. Critics have suggested that evidence-based …
Ginsenoside 20 (S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway
B Peng, R He, Q Xu, Y Yang, Q Hu, H Hou… - Pharmacological …, 2019 - Elsevier
Metastasis is the primary cause of cancer recurrence and cancer related mortality in triple-
negative breast cancer (TNBC). EGFR overexpression is in 50–75% TNBC and EGFR …
negative breast cancer (TNBC). EGFR overexpression is in 50–75% TNBC and EGFR …
The butterfly effect in cancer: a single base mutation can remodel the cell
We have compared the proteome, transcriptome, and metabolome of two cell lines: the
human breast epithelial line MCF-10A and its mutant descendant MCF-10A-H1047R. These …
human breast epithelial line MCF-10A and its mutant descendant MCF-10A-H1047R. These …
[HTML][HTML] MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
DA Franklin, JT Sharick, PI Ericsson-Gonzalez… - JCI insight, 2020 - ncbi.nlm.nih.gov
Triple-negative breast cancers (TNBCs) are heterogeneous and aggressive, with high
mortality rates. TNBCs frequently respond to chemotherapy, yet many patients develop …
mortality rates. TNBCs frequently respond to chemotherapy, yet many patients develop …
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of …
C Iavarone, IK Zervantonakis, LM Selfors… - Molecular cancer …, 2019 - AACR
Most patients with late-stage high-grade serous ovarian cancer (HGSOC) initially respond to
chemotherapy but inevitably relapse and develop resistance, highlighting the need for novel …
chemotherapy but inevitably relapse and develop resistance, highlighting the need for novel …